Nuvectis Pharma Stock (NASDAQ:NVCT)

Revenue Ownership Financials Chart

Previous Close

$7.39

52W Range

$4.44 - $11.52

50D Avg

$6.19

200D Avg

$7.54

Market Cap

$192.83M

Avg Vol (3M)

$105.27K

Beta

-0.28

Div Yield

-

NVCT Company Profile

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Feb 04, 2022

Website

NVCT Performance

NVCT Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	$149.00K
Operating Income	-	$-22.90M	$-19.23M
Net Income	$-19.00M	$-22.26M	$-18.79M
EBITDA	-	$-22.90M	$-19.23M
Basic EPS	$-1.11	$-1.43	$-1.48
Diluted EPS	$-1.11	$-1.43	$-1.48

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
MIST	Milestone Pharmaceuticals Inc.
MOLN	Molecular Partners AG
TNXP	Tonix Pharmaceuticals Holding Corp.
CRDF	Cardiff Oncology, Inc.
RANI	Rani Therapeutics Holdings, Inc.
IPHA	Innate Pharma S.A.
SAVA	Cassava Sciences, Inc.
CGEN	Compugen Ltd.